| Title : Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials - Monami_2010_Nutr.Metab.Cardiovasc.Dis_20_224 |
| Author(s) : Monami M , Iacomelli I , Marchionni N , Mannucci E |
| Ref : Nutr Metab Cardiovasc Dis , 20 :224 , 2010 |
| Abstract : BACKGROUND AND AIM: The role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes is debated; many recent trials, which were not included in previous meta-analyses, could add relevant information. METHODS AND RESULTS: All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with DPP-4 inhibitors, with a duration >12 weeks were meta-analyzed for HbA1c, BMI, hypoglycemia, and other adverse events. A total of 41 RCTs (9 of which are unpublished) was retrieved and included in the analysis. Gliptins determine a significant improvement of HbA1c in comparison with a placebo (-0.7 [-0.8:-0.6]), with a low risk of hypoglycemia. DPP-4 inhibitors show a similar efficacy in monotherapy and in combination with other agents. The risk of cardiovascular events and all-cause death with DPP-4 inhibitors is 0.76 [0.46-1.28] and 0.78 [0.40-1.51], respectively. CONCLUSIONS: DPP-4 inhibitors reduce HbA1c, although to a lesser extent than sulphonylureas, with no weight gain and no hypoglycemic risk; further data are needed to assess their long-term safety. |
| ESTHER : Monami_2010_Nutr.Metab.Cardiovasc.Dis_20_224 |
| PubMedSearch : Monami_2010_Nutr.Metab.Cardiovasc.Dis_20_224 |
| PubMedID: 19515542 |
Monami M, Iacomelli I, Marchionni N, Mannucci E (2010)
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
Nutr Metab Cardiovasc Dis
20 :224
Monami M, Iacomelli I, Marchionni N, Mannucci E (2010)
Nutr Metab Cardiovasc Dis
20 :224